nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.07.2007 | Original article

¹⁸F-fluorothymidine kinetics of malignant brain tumors

verfasst von: Christiaan Schiepers, Wei Chen, Magnus Dahlbom, Timothy Cloughesy, Carl K. Hoh, Sung-Cheng Huang

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

¹⁸F-labeled deoxy-fluorothymidine (FLT), a marker of cellular proliferation, has been used in PET tumor imaging. Here, the FLT kinetics of malignant brain tumors were investigated.

Methods

Seven patients with high-grade tumors and two patients with metastases had 12 studies. After 1.5 MBq/kg ¹⁸F-FLT had been administered intravenously, dynamic PET studies were acquired for 75 min. Images were reconstructed with iterative algorithms, and corrections applied for attenuation and scatter. Parametric images were generated with factor analysis, and vascular input and tumor output functions were derived. Compartmental models were used to estimate the rate constants.

Results

The standard three-compartment model appeared appropriate to describe ¹⁸F-FLT uptake. Corrections for blood volume, metabolites, and partial volume were necessary. Kinetic parameters were correlated with tumor pathology and clinical follow-up data. Two groups could be distinguished: lesions that were tumor predominant (TumP) and lesions that were treatment change predominant (TrcP). Both groups had a widely varying k ₁ (transport across the damaged BBB, range 0.02–0.2). Group TrcP had a relatively low k ₃ (phosphorylation rate, range 0.017–0.027), whereas k ₃ varied sevenfold in group TumP (range 0.015–0.11); the k ₃ differences were significant (p < 0.01). The fraction of transported FLT that is phosphorylated [k ₃/(k ₂+k ₃)] was able to separate the two groups (p < 0.001).

Conclusion

A three-compartment model with blood volume, metabolite, and partial volume corrections could adequately describe ¹⁸F-FLT kinetics in malignant brain tumors. Patients could be distinguished as having: (1) tumor-predominant or (2) treatment change-predominant lesions, with significantly different phosphorylation rates.

Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4(11):1334–6.PubMedCrossRef

Shields AF. PET imaging with ¹⁸F-FLT and thymidine analogs: promise and pitfalls. J Nucl Med 2003;44(9):1432–4.PubMed

Toyohara J, Waki A, Takamatsu S, Yonekura Y, Magata Y, Fujibayashi Y. Basis of FLT as a cell proliferation marker: comparative uptake studies with [³H]thymidine and [³H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol 2002;29(3):281–7.PubMedCrossRef

Seitz U, Wagner M, Neumaier B, Wawra E, Glatting G, Leder G, et al. Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3′-[¹⁸F]fluoro-3′-deoxythymidine ([¹⁸F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging 2002;29(9):1174–81.PubMedCrossRef

Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, et al. Imaging proliferation in brain tumors with ¹⁸F-FLT PET: comparison with ¹⁸F-FDG. J Nucl Med 2005;46(6):945–52.PubMed

Cobben DC, Elsinga PH, Hoekstra HJ, Suurmeijer AJ, Vaalburg W, Maas B, et al. Is ¹⁸F-3′-fluoro-3′-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer? J Nucl Med 2004;45(10):1677–82.PubMed

Francis DL, Visvikis D, Costa DC, Croasdale I, Arulampalam TH, Luthra SK, et al. Assessment of recurrent colorectal cancer following 5-fluorouracil chemotherapy using both ¹⁸FDG and ¹⁸FLT PET. Eur J Nucl Med Mol Imaging 2004;31(6):928.PubMedCrossRef

Cobben DC, van der Laan BF, Maas B, Vaalburg W, Suurmeijer AJ, Hoekstra HJ, et al. ¹⁸F-FLT PET for visualization of laryngeal cancer: comparison with ¹⁸F-FDG PET. J Nucl Med 2004;45(2):226–31.PubMed

Visvikis D, Francis D, Mulligan R, Costa DC, Croasdale I, Luthra SK, et al. Comparison of methodologies for the in vivo assessment of ¹⁸FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging 2004;31(2):169–78.PubMedCrossRef

10.

Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, Peterson L, et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 2005;46(2):274–82.PubMed

11.

Muzi M, Mankoff DA, Grierson JR, Wells JM, Vesselle H, Krohn KA. Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med 2005;46(2):371–80.PubMed

12.

Yun M, Oh SJ, Ha HJ, Ryu JS, Moon DH. High radiochemical yield synthesis of 3′-deoxy-3′-[¹⁸F]fluorothymidine using (5′-O-dimethoxytrityl-2′-deoxy-3′-O-nosyl-beta-D-threo pentofuranosyl)thymine and its 3-N-BOC-protected analogue as a labeling precursor. Nucl Med Biol 2003;30(2):151–7.PubMedCrossRef

13.

Nuyts J, Baete K, Beque D, Dupont P. Comparison between MAP and postprocessed ML for image reconstruction in emission tomography when anatomical knowledge is available. IEEE Trans Med Imaging 2005;24(5):667–75.PubMedCrossRef

14.

Nuyts J, Michel C, Dupont P. Maximum-likelihood expectation-maximization reconstruction of sinograms with arbitrary noise distribution using NEC-transformations. IEEE Trans Med Imaging 2001;20(5):365–75.PubMedCrossRef

15.

Schiepers C, Hoh CK, Dahlbom M, Wu HM, Phelps ME. Factor analysis for delineation of organ structures, creation of in- and output functions, and standardization of multicenter kinetic modeling. Proc SPIE 1999;3661:1343–50.CrossRef

16.

Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979;6(5):371–88.PubMedCrossRef

17.

Huang SC, Phelps ME, Hoffman EJ, Sideris K, Selin CJ, Kuhl DE. Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 1980;238(1):E69–82.PubMed

18.

Schiepers C, Wu HM, Nuyts J, Dahlbom M, Hoh CK, Huang SC, et al. F-18 fluoride PET: Is non-invasive quantitation feasible with factor analysis? J Nucl Med 1997;38(5 Suppl):93P.

19.

Schiepers C, Hoh CK, Dahlbom M, Wu HM, Phelps ME. Reproducibility of input functions obtained with factor analysis in breast cancer. J Nucl Med 1998;39(5 Suppl):165P.

20.

Schiepers C, Hoh CK, Seltzer MA, Phelps ME, Dahlbom M. Factor analysis for quantification of ¹¹C-acetate PET in primary prostate cancer. J Nucl Med 2000;41(5 Suppl):100P.

21.

Schiepers C, Hoh CK, Nuyts J, Wu HM, Phelps ME, Dahlbom M. Factor analysis in prostate cancer: delineation of organ structures and automatic generation of in- and output functions. IEEE Trans Nucl Sci 2002;49(5):2338–43.CrossRef

22.

Wu HM, Hoh CK, Choi Y, Schelbert HR, Hawkins RA, Phelps ME, et al. Factor analysis for extraction of blood time-activity curves in dynamic FDG-PET studies. J Nucl Med 1995;36(9):1714–22.PubMed

23.

Schiepers C, Czernin J, Hoh CK, Nuyts J, Phelps ME, Dahlbom M. Factor analysis for automatic determination of myocardial flow in ¹³N-ammonia PET studies. J Nucl Med 2002;43(5 Suppl):52P.

24.

Schiepers C, Nuyts J, Wu HM, Verma RC. PET with ¹⁸F-fluoride: effects of iterative versus filtered backprojection reconstruction on kinetic modeling. IEEE Trans Nucl Sci 1997;44:1591–9.CrossRef

25.

Schiepers C, Nuyts J, Wu HM, Dahlbom M, Huang SC, Phelps ME. Influence of iterative reconstruction on parameter estimation with three-compartment kinetic modeling. J Nucl Med 1997;38(5 Suppl):102P.

26.

Wells JM, Mankoff DA, Eary JF, Spence AM, Muzi M, O’Sullivan F, et al. Kinetic analysis of 2-[¹¹C]thymidine PET imaging studies of malignant brain tumors: preliminary patient results. Mol Imaging 2002;1(3):145–50.PubMedCrossRef

27.

Muzi M, Spence AM, O’Sullivan F, Mankoff DA, Wells JM, Grierson JR, et al. Kinetic analysis of 3′-deoxy-3′-¹⁸F-fluorothymidine in patients with gliomas. J Nucl Med 2006;47(10):1612–21.PubMed

Titel: 18F-fluorothymidine kinetics of malignant brain tumors
verfasst von: Christiaan Schiepers
Wei Chen
Magnus Dahlbom
Timothy Cloughesy
Carl K. Hoh
Sung-Cheng Huang
Publikationsdatum: 01.07.2007
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2007
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-006-0354-5

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2007

Normal limits of ejection fraction and volumes determined by gated SPECT in clinically normal patients without cardiac events: a study based on the J-ACCESS database

The 68Ge/68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine?

Radiopharmaceutical therapy of bone metastases with 89SrCl2, 186Re-HEDP and 153Sm-EDTMP: a dosimetric study using Monte Carlo simulation

Spatial dose distributions in solid tumors from 186Re transported by liposomes using HS radiochromic media

Reply

The expanding role of left ventricular functional assessment using gated myocardial perfusion SPECT: the supporting actor is stealing the scene